"Inactive" excipients such as Cremophor can affect in vivo drug disposition

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 5, 2003, Pages 394-396

  Wandel, Cristoph ^b   Kim, Richard B ^b   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CASTOR OIL; CREMOPHOR; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; EXCIPIENT; GLYCOPROTEIN P; PACLITAXEL; POLYSORBATE 80;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG PACKAGING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INTESTINE ABSORPTION; MICROEMULSION; NOTE; PRIORITY JOURNAL;

CARDIOTONIC AGENTS; DIGOXIN; EXCIPIENTS; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS;

EID: 0037540055     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00010-9     Document Type: Note

References (19)

1. Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-405.
2. Bailey DG, Arnold JM, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53:637-42.
3. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
4. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70:462-7.
5. Darbar D, Dell'Orto S, Morike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997;61:292-300.
6. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002;72:247-55.
7. Pifferi G, Santoro P, Pedrani M. Quality and functionality of excipients. Farmaco 1999;54:1-14.
8. Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol 2000;32:210-8.
9. Scott AW. Non-medicinal ingredients. Drug Safety 1990;5(Suppl 1):95-100.
10. Boman G, Lundgren P, Stjernstrom G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 1975;8:293-9.
11. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998;4:1937-42.
12. Schuurhuis GJ, Broxterman HJ, Pinedo HM, van Heijningen TH, van Kalken CK, Vermorken JB, et al. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 1990;62:591-4.
13. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996;59:297-303.
14. Wandel C, Kim RB, Wood AJJ, Stein CM. "Inactive" ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A [abstract]. Clin Pharmacol Ther 2001;69:P66.
15. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8.
16. Rege B, Kao J, Polli J. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237-46.
17. Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, et al. Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 2000;50:576-9.
18. Bardelmeijer HA, Ouwehand M, Malingre MM, Schellens JH, Beijnen JH, van Tellingen O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 2002;49:119-25.
19. Malingre MM, Schellens JH, van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, et al. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001;85:1472-7.